Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueGross MarginNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Sales

Pharming (PHAR) Return on Sales (2021 - 2025)

Historic Return on Sales for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to 1.37%.

  • Pharming's Return on Sales rose 12800.0% to 1.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 1900.0%. This contributed to the annual value of 0.04% for FY2024, which is 200.0% down from last year.
  • According to the latest figures from Q3 2025, Pharming's Return on Sales is 1.37%, which was up 12800.0% from 0.05% recorded in Q2 2025.
  • Over the past 5 years, Pharming's Return on Sales peaked at 4.85% during Q1 2022, and registered a low of 0.37% during Q1 2024.
  • Over the past 5 years, Pharming's median Return on Sales value was 0.0% (recorded in 2021), while the average stood at 0.3%.
  • Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 48500bps in 2022, then tumbled by -47700bps in 2023.
  • Pharming's Return on Sales (Quarter) stood at 0.16% in 2021, then crashed by -289bps to 0.31% in 2022, then soared by 73bps to 0.08% in 2023, then increased by 22bps to 0.07% in 2024, then soared by 2183bps to 1.37% in 2025.
  • Its Return on Sales was 1.37% in Q3 2025, compared to 0.05% in Q2 2025 and 0.05% in Q1 2025.